Literature DB >> 7864703

Prevalence, age distribution, and gender of patients with atrial fibrillation. Analysis and implications.

W M Feinberg1, J L Blackshear, A Laupacis, R Kronmal, R G Hart.   

Abstract

The prevalence of atrial fibrillation (AF) is related to age. Anticoagulation is highly effective in preventing stroke in patients with AF, but the risk of hemorrhage may be increased in older patients. We reviewed the available epidemiologic data to define the age and sex distribution of people with AF. From four large recent population-based surveys, we estimated the overall age- and gender-specific prevalence of AF. These estimates were applied to the recent US census data to calculate the number of men and women with AF in each age group. There are an estimated 2.2 million people in the United States with AF, with a median age of about 75 years. The prevalence of AF is 2.3% in people older than 40 years and 5.9% in those older than 65 years. Approximately 70% of individuals with AF are between 65 and 85 years of age. The absolute number of men and women with AF is about equal. After age 75 years, about 60% of the people with AF are women. In contrast to people with AF in the general population, patients with AF in recent anticoagulation trials had a mean age of 69 years, and only 20% were older than 75 years. The risks and benefits of antithrombotic therapy in older individuals are important considerations in stroke prevention in AF.

Entities:  

Mesh:

Year:  1995        PMID: 7864703

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN: 0003-9926


  469 in total

Review 1.  Long-term anticoagulation therapy for atrial fibrillation in elderly patients: efficacy, risk, and current patterns of use.

Authors:  D McCormick; J H Gurwitz; R J Goldberg; J Ansell
Journal:  J Thromb Thrombolysis       Date:  1999-04       Impact factor: 2.300

2.  Using anticoagulation or aspirin to prevent stroke. Research was methodologically flawed.

Authors:  S J Ellis; R Hans
Journal:  BMJ       Date:  2000-04-08

3.  Community impact of anticoagulation services: rationale and design of the Managing Anticoagulation Services Trial (MAST).

Authors:  D B Matchar; G P Samsa; S J Cohen; E Z Oddone
Journal:  J Thromb Thrombolysis       Date:  2000-06       Impact factor: 2.300

4.  Anticoagulation to prevent stroke in atrial fibrillation. It's still not clear whether results in secondary care translate to primary care.

Authors:  D A Fitzmaurice; J Mant; E T Murray; F D Hobbs
Journal:  BMJ       Date:  2000-11-04

Review 5.  Report of the NASPE/NHLBI Round Table on Future Research Directions in Atrial Fibrillation. North American Society of Pacing and Electrophysiology.

Authors:  S Saskena; M J Domanski; E J Benjamin; A J Camm; M D Ezekowitz; B J Gersh; J Jalife; G V Naccarelli; R E Vlietstra; D G Wyse
Journal:  J Interv Card Electrophysiol       Date:  2001-09       Impact factor: 1.900

Review 6.  Which patient should be referred to an electrophysiologist: supraventricular tachycardia.

Authors:  Richard J Schilling
Journal:  Heart       Date:  2002-03       Impact factor: 5.994

Review 7.  Atrial fibrillation: is rate stabilization a valid clinical strategy?

Authors:  S H Hohnloser
Journal:  Ann Noninvasive Electrocardiol       Date:  2001-04       Impact factor: 1.468

Review 8.  Very low-intensity antithrombotic therapy in atrial fibrillation.

Authors:  B G Koefoed; P Petersen
Journal:  J Thromb Thrombolysis       Date:  1999-01       Impact factor: 2.300

Review 9.  Genetics of cardiovascular disease with emphasis on atrial fibrillation.

Authors:  R Brugada; J Brugada; R Roberts
Journal:  J Interv Card Electrophysiol       Date:  1999-03       Impact factor: 1.900

10.  Treatment of long-duration atrial fibrillation by modified maze procedure.

Authors:  Pankaj Kumar; Thanos Athanasiou; Rex De L Stanbridge
Journal:  J R Soc Med       Date:  2002-11       Impact factor: 5.344

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.